Researchers presented on Thursday at the American Society of Tropical Medicine and Hygiene annual meeting that L9LS monoclonal antibody was 78% effective against malaria over six months in Malian infants versus placebo. [1]
Study researchers reported that administering L9LS prior to R21 malaria vaccine reduced vaccine-induced antibody levels by 20% to 30% in tested infants. [2] The PfSPZ-LARC2 malaria vaccine achieved 87% efficacy in preventing infection during a Phase 1 trial. [3] Researchers identified pregnant people and children recently discharged after malaria hospitalization as priority groups for future L9LS testing. [4]
Study lead Robert Seder stated that researchers will prioritize non-infant patient groups for L9LS pivotal trials planned to start in 2028. [5] In the trial, all 7 placebo recipients became infected after malaria challenge, while only 2 of 15 vaccinated participants developed infection. [6] The PfSPZ-LARC2 vaccine was found to be safe and well tolerated by trial participants. [7]
Dr. Sean C. Murphy led reporting of the trial findings, with trial operations led by UW Medicine and partner institutions. [8]Investigadores presentaron el jueves en la reunión anual de la Sociedad Estadounidense de Medicina Tropical e Higiene que el anticuerpo monoclonal L9LS tuvo una efectividad del 78% contra la malaria durante seis meses en lactantes de Malí, en comparación con el placebo. [1]
Los investigadores del estudio informaron que la administración de L9LS antes de la vacuna contra la malaria R21 redujo los niveles de anticuerpos inducidos por la vacuna entre un 20% y un 30% en los lactantes evaluados. [2] La vacuna contra la malaria PfSPZ-LARC2 alcanzó una eficacia del 87% en la prevención de infecciones durante un ensayo de Fase 1. [3] Los investigadores identificaron a las personas embarazadas y a los niños dados de alta recientemente tras hospitalización por malaria como grupos prioritarios para futuras pruebas con L9LS. [4]
El director del estudio Robert Seder declaró que los investigadores priorizarán grupos de pacientes no lactantes para los ensayos pivote de L9LS, cuya puesta en marcha está prevista para 2028. [5] En el ensayo, todos los 7 receptores de placebo contrajeron la infección tras la exposición controlada a la malaria, mientras que solo 2 de los 15 participantes vacunados desarrollaron la infección. [6] Se comprobó que la vacuna PfSPZ-LARC2 es segura y bien tolerada por los participantes del ensayo. [7]
El Dr. Sean C. Murphy dirigió la presentación de los resultados del ensayo, mientras que las operaciones del mismo estuvieron a cargo de UW Medicine y las instituciones asociadas. [8]
Proof8 sources · 2 publishers · signed
What this stands on
Researchers presented on Thursday at the American Society of Tropical Medicine and Hygiene annual meeting that L9LS monoclonal antibody was 78% effective against malaria over six months in Malian infants versus placebo. · STAT
Study researchers reported that administering L9LS prior to R21 malaria vaccine reduced vaccine-induced antibody levels by 20% to 30% in tested infants. · STAT
The PfSPZ-LARC2 malaria vaccine achieved 87% efficacy in preventing infection during a Phase 1 trial. · Medical Xpress
Researchers identified pregnant people and children recently discharged after malaria hospitalization as priority groups for future L9LS testing. · STAT
Study lead Robert Seder stated that researchers will prioritize non-infant patient groups for L9LS pivotal trials planned to start in 2028. · STAT
In the trial, all 7 placebo recipients became infected after malaria challenge, while only 2 of 15 vaccinated participants developed infection. · Medical Xpress
The PfSPZ-LARC2 vaccine was found to be safe and well tolerated by trial participants. · Medical Xpress
Dr. Sean C. Murphy led reporting of the trial findings, with trial operations led by UW Medicine and partner institutions. · Medical Xpress
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
Article provenance · signed receipt ✓ · 8 sources · v 001The worldThe recordThe writingThe filing
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Friday, November 20, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.